Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31), Briefing.com reports. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The business had revenue of $108.83 million for the quarter, compared to analyst estimates of $116.03 million. During the same period last year, the firm earned ($2.33) earnings per share. The company’s quarterly revenue was up 8.3% on a year-over-year basis.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock traded down $0.45 during trading on Friday, hitting $42.75. 1,143,019 shares of the stock were exchanged, compared to its average volume of 786,481. Ultragenyx Pharmaceutical has a 12 month low of $31.52 and a 12 month high of $54.98. The stock’s fifty day moving average is $47.25 and its 200 day moving average is $44.08. The stock has a market cap of $3.55 billion, a PE ratio of -5.32 and a beta of 0.68.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on RARE shares. Robert W. Baird raised their price target on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Canaccord Genuity Group upped their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday. TD Cowen lifted their target price on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Wedbush lowered their price target on Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating for the company in a report on Friday. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $88.00.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $201,922.56. Following the completion of the transaction, the executive vice president now owns 67,340 shares in the company, valued at approximately $3,620,198.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $201,922.56. Following the completion of the transaction, the executive vice president now owns 67,340 shares in the company, valued at approximately $3,620,198.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Matthew K. Fust sold 12,195 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the completion of the sale, the director now directly owns 14,860 shares of the company’s stock, valued at approximately $756,076.80. The disclosure for this sale can be found here. Insiders have sold a total of 32,116 shares of company stock worth $1,645,983 in the last ninety days. 6.80% of the stock is owned by insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.